Introduction
============

Angelicae Sinensis Radix (AS), also known as Danggui in China, has been used widely in Asia for thousands of years because of its pharmaceutical effects on gynecological, cardiovascular and cerebrovascular diseases. In recent years, the pharmacological activities of this herb in mental diseases, has attracted attention. Previous reports have demonstrated that AS ethanol extract could attenuate CUMS-induced depressive symptoms by mediating the brain derived neurotrophic factor (BDNF) signaling pathway ([@B32]). AS water extracts also significantly decreased the immobility time of mice in both a tail suspension test (TST) and a forced swimming test (FST) through improving the content of monoamine neurotransmitters and neurotrophic factor in the hippocampus ([@B20]). This evidence proved that AS possessed an exact antidepressant effect. On the other hand, AS is frequently used in classical anti-depressant formulas, such as Xiaoyao San ([@B38]) and Danggui Shaoyao San ([@B41]; [@B48]). In addition, several reports demonstrated that some main constituents of AS indeed possessed anti-depression activity. For example, ferulic acid (FA) induced anti-depression via modulating the serotonergic system, regulating the HPA axis, and increasing ghrelin ([@B47]; [@B43]). Vanillic acid reversed the dysfunction of cognitive and memory induced oxidative stress via reducing AChE, TNF-α, and corticosterone ([@B33]). Butylphthalide improved lipopolysaccharide-induced depressive-like behavior in rats by regulating Nrf2 and NF-κB pathways ([@B42]). Despite the discovery of the anti-depression effect of AS, the underlying mechanism has not been investigated yet.

In recent years, several related studies suggested that depression is associated with anemia ([@B25]; [@B37]). On the one hand, malnutrition in depressed patients may contribute to anemia ([@B21]; [@B30]). On the other hand, anemia directly affects brain function and can result in cognitive impairment ([@B29]), which contributes to the development of depression. Poorer physical performance associated with anemia has detrimental consequences on life quality and further promotes the development of depression ([@B27]). Additionally, underlying diseases such as renal failure or inflammatory diseases could result in the development of both anemia and depression ([@B6]; [@B8]; [@B12]).

According to the theory of traditional Chinese medicine (TCM), depression could be ameliorated via modulating the blood system ([@B7]). It is believed that blood deficiency is the cause of recurrent melancholia ([@B5]). Therefore, hematinic and blood-nourishing medicines were usually used in classical anti-depressant formulas to enhance its therapeutic effect ([@B44]). For example, *Ligusticum chuanxiong* Hort was used in Yueju, to regulate the blood system in depressed patients ([@B31]). Commonly, AS was used by traditional Chinese physicians to replenish the blood and promote circulation ([@B50]). We speculated that the anti-depression effect of AS is related to the pharmacological activity of modulating the blood system.

Metabonomics, a crucial platform of systems biology, could explore the pathways associated with the pathological state and pharmacological action of drugs ([@B28]; [@B45]). Located downstream of transcriptomics and proteomics, metabolomics reflects the terminal state of the metabolic network. Because it can evaluate the therapeutic effect by comprehensively detecting and quantifying the metabolite variations in biological systems, the method is especially suitable for the evaluation of the holistic and synergistic effects of TCM ([@B40]). Metabonomics has been used to explore the enriching blood mechanism of AS in previous reports ([@B19], [@B18]; [@B39]; [@B15]). In the current study, metabolomics was performed, based on ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) and nuclear magnetic resonance (NMR), to elucidate the anti-depression mechanisms of AS. The metabolites regulated by AS in depression were compared with that in anemia. The shared metabolites and pathways regulated in both the depression and anemia model, through the administration of AS, were further analyzed.

The aim of the current study is to elucidate the potential anti-depression mechanisms of AS that are related to the activity of modulating the blood system. Firstly, the model of CUMS was performed to assess the anti-depression effect of AS. Secondly, blood routine examinations and blood gas determinations were conducted to demonstrate that AS specifically reverses the disorder of the blood system induced by the CUMS procedure. Thirdly, a metabolomic approach based on UPLC-MS/MS combined with ^1^H NMR was employed to analyze the endogenous metabolites and metabolic pathways regulated by AS in depression. The disturbed metabolites and pathways were then regulated in an anemia model, through the administration of AS, summarized from previous literature and compared with that in depression in the present study. Finally, the expression of critical proteins on revealed signaling pathways, were further determined by western blotting.

Materials and Methods {#s1}
=====================

Chemicals and Reagents
----------------------

The radix of *Angelica sinensis* (*Oliv*.) Diels was purchased from the Shanxi Huayang Pharmaceutical Company and authenticated by Prof. Xue-Mei Qin (Shanxi University). Voucher specimens were deposited in the Modern Research Center for Traditional Chinese Medicine of Shanxi University. Chromatography grade methanol, acetonitrile and formic acid were obtained from Thermo Fisher Scientific Inc. (Waltham, MA, United States). Agar (Analytical grade). Deionized water was purified using a Milli-Q system (Billerica, MA, United States). i-STAT^®^ EG7+ was purchased from Abbott (Chicago, IL, United States). Venlafaxine hydrochloride was obtained from Kang Hong Pharmaceutical (Chengdu, China).

Preparation of AS Extracts
--------------------------

The roots (4 kg) were extracted twice with 75% ethanol (1:8) under reflux, every time for 2 h, and the combined extracts were filtrated and concentrated in vacuo to a syrup. The syrup was then lyophilized into powders (48.1% yield).

Animals and Drug Administration
-------------------------------

A total of 60 healthy male Sprague-Dawley (SD) rats (weighing 180 ± 20 g) were obtained from the Beijing Vital Laboratory \[Co. SCXK (Jing) 2016-0011\]. All of the rats were adapted to the new experimental environment (12 h light dark cycle, 22 ± 2°C of room temperature) with free access to food and water for 1 week. The study was approved by the Experimental Animal Ethical Committee of Modern Research Center for Traditional Chinese Medicine, Shanxi University. All experimental procedures in the present study were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals (United States) and the Prevention of Cruelty to Animals Act (1986) of China.

After 1 week of acclimatization, the rats were randomly divided into five groups with 12 rats in each: the control (NS), model (MS), venlafaxine (VLF), high dose group of AS (HAS), and low dose group of AS (LAS) groups. The venlafaxine group of animals served as the positive control. For the next 28 days, the rats in the HAS and LAS group were given 15 and 7.5 g herb/kg AS according to the effective dose reported in previous research ([@B32]; [@B20]), the rats in the VLF group were intragastrically given 35 mg/kg venlafaxine. Animals were given the calculated amounts of fractions with the administration of a volume of 10 mL/kg (rat body weight), the rats in the control and model groups were given water. AS extract was dissolved in water with concentrations of 0.72 and 0.36 g/ml. Venlafaxine was dissolved in water with concentrations of 3.5 mg/ml. The experimental design of the study is depicted in [Figure 1A](#F1){ref-type="fig"}.

![Effects of CUMS and drug treatment on behavior. **(A)** Study design. **(B)** Sucrose preference. **(C)** Body weight on day 28. **(D)** Body weight recorded weekly. **(E)** Crossing numbers in OFT. **(F)** Rearing numbers in OFT. **(G)** Immobility time in the FST. The data are presented as means ± SD (*n* = 12). ^\#\#^*p* \< 0.01 compared with control group; ^∗∗^*p* \< 0.01 compared with the CUMS group.](fphar-10-00192-g001){#F1}

Chronic Unpredictable Mild Stress (CUMS) Procedure
--------------------------------------------------

The CUMS procedure was carried out as described previously ([@B34]; [@B13]), with minor modifications. The rats in the MS, VLF, HAS, and LAS groups were stimulated by the following stressors randomly between 9:00 and 11:00 a.m. every day and housed separately for 4 weeks. The stressors included: noises for 3 h (60 dB), swimming in the water at 4°Cfor 5 min, exposure to a hot room at 45°C for 10 min, deprivation for 24 h, food deprivation for 24 h, constraint for 2 h, tail clamp for 2 min, day--night reversal (12 h/12 h), unpredictable foot shocks for 2 min (36V, one shock/2 s, 10 s duration).

Behavior Test
-------------

### Open-Field Test (OFT)

The open-field test was, respectively, carried out at days 0, 7, 14, 21, and 28 to evaluate the general locomotor activity and depression-like behavior of rats ([@B49]). The open field apparatus was a 100 cm × 100 cm × 40 cm black box containing 25 equal square regions that were defined by lines on the floor of the box. Every rat was placed into the center of the box and observed for 5 min. The crossing and rearing numbers were recorded.

### Sucrose Preference Test (SPT)

The sucrose preference test was conducted at days 0 and 28 to quantify anhedonia, an important symptom of major depressive disorder (MDD). The test was performed as described previously ([@B49]). All rats were trained before the test was carried out. Briefly, two bottles of sucrose solution (1%, w/v) were given to rats for 24 h, and then one of them was replaced with water for another 24 h. After a training session, the rats were deprived of water and food for 12 h, followed by free access to one bottle of a sucrose solution and another bottle of water for another 12 h. The weight of the consumed water and sucrose solution was measured and recorded. The sucrose preference rate was calculated as follows: consumed sucrose solution/(consumed sucrose + solution consumed water).

### Forced Swim Test

The forced swim test was carried out as previously described ([@B46]). The FST apparatus was a cylindrical container (50 cm in height and 20 cm in diameter) filled with water at 25 ± 2°C to a depth of 30 cm. Every rat was exposed to a pre-test for 15 min on the 1st day, and the FST was carried out on the next day. All rats were compelled to swim for 6 min. The immobility time was recorded during the last 4 min when the rats floated with their heads above the water and without struggling.

Blood Collection, Blood Routine, and Blood Gas Determination
------------------------------------------------------------

Twenty-four hours after the last intragastric administration, the blood of all rats was collected into a vacuum blood collection tube through an abdominal aortic method. 1.5 mL whole blood was collected into anticoagulant tubes containing ethylenediaminetetraacetic acid (EDTA) for peripheral blood routine examination by automated hematology analyzers. 1 mL whole blood was collected into heparinized anticoagulant tubes for blood gas determination. The remaining blood samples were collected into a vacuum blood collection tube without an anticoagulant, and immediately centrifuged at 3,000 rpm for 10 min. The serum was then collected into EP tubes and frozen at -80°C until LC-MS analysis.

Metabolomics Study
------------------

### Sample Preparation for Metabolomics Study

Serum samples were thawed at room temperature. For LC--MS metabolomics analysis, 100 μL serum samples were extracted with a mix of 225 μL methanol and 75 μL acetonitrile to precipitate protein, and the mixture was then vortexed for 2 min and centrifuged at 13,000 rpm for 15 min at 4°C. A quality control (QC) sample was prepared from 10 μL of each test sample. For NMR metabolomics analysis, 350 μL of D~2~O was added to 450 μL of the serum sample, and the mixture was then vortexed for 30 s, followed by centrifugation at 13,000 rpm for 20 min at 4°C. 550 μL of supernatant from the serum sample was transferred into a 5 mm NMR tube for NMR analysis.

### LC--MS and NMR Method

A Dionex UltiMate 3000 UHPLC system combined with a Q Exactive Orbitrap-MS spectrometer and a Xcalibur workstation (Thermo Fisher Scientific Inc., Waltham, MA, United States) was used to acquire LC--MS data. An Acquity UPLC HSS T3 column was used for chromatographic separation. The mobile phase system included water/0.1% formic acid (solvent A) and acetonitrile/0.1% formic acid (solvent B) under a gradient elution as follows: 0 ∼ 2 min, 2% B; 2 ∼ 3 min, 2% B to 35% B; 3 ∼ 15 min, 35% B to 70% B; 15 ∼ 18 min, 70% B; 18 ∼ 29 min, 70% B to 98% B; 29 ∼ 31 min, 98% B; 31 ∼ 33 min, 98% B to 2% B; 33 ∼ 35 min, 2% B. The flow rate was set at 0.2 ml/min. The injection volume was 5 μL. All samples were analyzed under positive and negative ionization modes via a heated electrospray ionization (HESI) source. The detailed parameters were as follows: spray voltage of 3.5 kV for the positive mode and 2.5 kV for the negative mode, the capillary temperature of 320°C, the sheath of 35 arbitrary units, auxiliary gas flow rates of 10 arbitrary units. The range of mass scanning was set from 100 to 1500 (m/z).

The ^1^H NMR spectra were recorded at 298 K on a Bruker 600 MHz AVANCE III spectrometer (Bruker Biospin, Rheinstetten, Germany). Each ^1^H NMR spectrum included 64 scans acquired over 5 min. The detailed parameters were as follows: relaxation delay of 1.0 s, spectral size of 65536 points, and spectral width of 12019.2 Hz.

### Data Analysis and the Screening of Potential Biomarkers

The acquired raw data from the LC--MS were introduced to the Compound Discoverer 2.0 (Thermo Fisher, United States) for peak alignment and detection. The primary parameters were: mass range, 100--1,500 Da; mass tolerance, 5 ppm; S/N threshold, 3; assignment threshold, 70. The peak area was normalized in Excel 2007. The obtained NMR spectra were introduced to MestReNova (version 8.0.1, Mestrelab Research, Santiago de Compostela, Spain) for phasing and correcting the baseline manually, and for referencing to the chemical shift of creatinine (3.04 ppm). Regions at δ 0.0--9.00 ppm were segmented at δ 0.01 intervals. Regions containing resonance from residual water (δ 4.50--5.00 ppm) were cut. The integral areas were then normalized to the total sum of spectra, to reduce the significant concentration differences.

The acquired data was imported into SIMCA-P V13.0 (Umetrics, Sweden) for multivariate statistical analysis. The different biological metabolites were selected based on VIP-value of S-plot (\>1) and *T*-test (*p* \< 0.05). The selected metabolites of the LC--MS analysis were identified according to the online databases: Metlin^[1](#fn01){ref-type="fn"}^, HMDB^[2](#fn02){ref-type="fn"}^, Massbank^[3](#fn03){ref-type="fn"}^, Pubchem^[4](#fn04){ref-type="fn"}^, Lipid Maps^[5](#fn05){ref-type="fn"}^ and KEGG^[6](#fn06){ref-type="fn"}^. The metabolites obtained from NMR analysis were identified based on moieties and chemical shifts. Pathway analysis was conducted with MetaboAnalyst^[7](#fn07){ref-type="fn"}^.

Western Blot Analysis
---------------------

The total proteins of the liver were extracted, and the concentrations were measured by a BCA procedure. Samples containing 50 μg proteins were separated by SDS-PAGE electrophoresis and transferred to PVDF membranes. The membranes were blocked with 5% bovine albumin (BSA) in Tris buffer saline-Tween 20 (TBST) for 2 h at 37°C, and then incubated overnight at 4°C with the respective first antibodies diluted in 1.5: 1000. After washing with TBST, the membranes were incubated with fluorescent secondary antibodies (1: 15000) for 2 h at 37°C. After rewashing with TBST, the membranes were scanned and visualized by a fluorescent scanner (Odyssey CLX, Gene Company Limited, United States).

Statistical Analysis
--------------------

Statistical analysis was performed using SPSS 16.0 software, and all data were expressed as mean ± standard deviation (SD). Statistical differences between two groups were compared by *T*-test and the significant differences between more groups were compared by one-way ANOVA. A value of *p* \< 0.05 was regarded as a significant difference.

Results
=======

The Anti-depression Effects of Angelicae Sinensis Radix on Behavior
-------------------------------------------------------------------

On day 0, no significant difference in sucrose preference, body weight or SPT were observed among the five groups (data not shown). After a 28-day CUMS treatment, the model group showed a significant decrease in sucrose preference compared with the control group ([Figure 1B](#F1){ref-type="fig"}). The treatment group of AS and VLF resulted in a significant increase in sucrose preference compared with the CUMS group, indicating a reduction of anhedonia. The result of body weight is shown in [Figure 1C,D](#F1){ref-type="fig"}. At the beginning of the experiment, no differences in body weight was shown among the five groups. On day 7, there were significant differences between the control and CUMS group. On days 21 and 28, the AS and VLF groups showed significantly higher body weight compared with the CUMS group. Similar results were observed in the OFT ([Figure 1E,F](#F1){ref-type="fig"}) and FST ([Figure 1G](#F1){ref-type="fig"}). After 28 days of the CUMS procedure, the crossing and rearing numbers in OFT were markedly lower, and the immobility time in FST was markedly longer in the CUMS group than the control group. After the treatment with AS and VLF for 28 days, these changes induced by CUMS were significantly attenuated.

Angelicae Sinensis Radix Reversed the Disorder of Peripheral Blood Routine Induced by CUMS
------------------------------------------------------------------------------------------

The results of peripheral blood routine analysis is presented in [Figure 2A--E](#F2){ref-type="fig"}. Compared with the control group, the level of red blood cells (RBC), platelet count (PLT), and red blood cell distribution width (RDW) in the CUMS group was significantly increased, while the level of monocyte proportion (MO%) and mean corpuscular volume (MCV) in the CUMS group was significantly decreased. After oral administration of AS, the reduced MO% and MCV were markedly increased, while elevated RBC and PLT were markedly decreased compared with the CUMS group. The administration of VLF could only reverse the abnormal peripheral blood indicators induced by on the CUMS procedure on MO% and MCV.

![Effects of CUMS and drug treatment on peripheral blood routine. **(A)** Erythrocyte count (RBC). **(B)** Platelet count (PLT). **(C)** Erythrocyte mean corpuscular volume (MCV). **(D)** Red blood cell distribution width (RDW) **(E)** Mono%. The data are presented as means ± SD (*n* = 12). ^\#\#^*p* \< 0.01 compared with control group; ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 compared with the CUMS group.](fphar-10-00192-g002){#F2}

Angelicae Sinensis Radix Reversed the Disorder of Blood Gas Induced by CUMS
---------------------------------------------------------------------------

The blood gas determination was performed on a blood gas analyzer (i-STAT 300, Abbott, United States). As presented in [Figure 3A,B](#F3){ref-type="fig"}, the partial pressure of oxygen (PO~2~) and oxygen saturation (sO~2~) in the CUMS group was significantly decreased compared with the control group, suggesting that depression is accompanied by hypoxia. On the contrary, the level of PO~2~ and sO~2~ was significantly increased after the treatment with AS and VLF. [Figure 3C,D](#F3){ref-type="fig"} shows that the CUMS treatment of rats for 28 days resulted in a significant increase in partial pressure of carbon dioxide (PCO~2~) and a significant decrease in hydrogen ion concentration (pH), indicating an occurrence of electrolyte disturbance. However, the phenomenon was reversed after the administration of AS.

![Effects of CUMS and drug treatment on blood gas. **(A)** Partial pressure of oxygen (PO~2~). **(B)** Oxygen saturation (sO~2~). **(C)** Hydrogen ion concentration (pH). **(D)** Partial pressure of carbon dioxide (PCO~2~). The data are presented as means ± SD (*n* = 8). ^\#\#^*p* \< 0.01 compared with control group; ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01 compared with the CUMS group.](fphar-10-00192-g003){#F3}

Angelicae Sinensis Radix Modulated the Blood System in CUMS-Induced Rats
------------------------------------------------------------------------

### Multivariate Data Analysis

The TIC chromatograms of serum samples from UPLC-MS/MS in both positive and negative modes are shown in [Figure 4](#F4){ref-type="fig"}, and a representative ^1^H NMR spectra of serum samples is shown in [Figure 5](#F5){ref-type="fig"}. The variables were, respectively, obtained from Compound Discoverer 2.0 and MestReNova software. These variables were then imported into SIMCA-P V13.0 for further multivariate statistical analysis. The partial least squares-discriminant analysis (PLS-DA) score plots from LC-MS and NMR both demonstrated that the rats in the CUMS group was obviously separated from the rats in the control group ([Figure 6A](#F6){ref-type="fig"}, [7A](#F7){ref-type="fig"}). The PLS-DA model was validated using the response of the permutation test ([Figure 6B](#F6){ref-type="fig"}, [7B](#F7){ref-type="fig"}). R^2^X of the PLS-DA model in LC-MS and NMR was 0.532 and 0.675, respectively; R^2^Y was 0.984 and 0.991; and *Q*^2^ was 0.699 and 0.92, suggesting that the model was excellent for prediction. The orthogonal partial least squares discriminant analysis (OPLS-DA) model was then applied to discriminate the differential metabolites contributing to the separation of the CUMS group and the control group. As shown in [Figure 6C](#F6){ref-type="fig"}, [7C](#F7){ref-type="fig"}, significant separations between the CUMS and the control group were observed in the OPLS-DA score plots. The S-plots of OPLS-DA revealed the variation of metabolites as shown in [Figure 6D](#F6){ref-type="fig"}, [7D](#F7){ref-type="fig"}. PLS-DA was future performed to investigate the regulatory effect of AS and VLF. [Figure 6E](#F6){ref-type="fig"}, [7E](#F7){ref-type="fig"} show that all experimental groups were obviously separated in both the LC-MS and NMR metabolic profile. Among them, the metabolic profiles in the AS and VLF group were closer to the control group than the CUMS group, suggesting that the metabolic disturbances induced by CUMS were reversed after drug treatment.

![Total positive ions and negative ions UPLC-MS/MS chromatograms of serum sample with the differential metabolites labeled. Numbers represent differential metabolites identified between the CUMS group and the control group.](fphar-10-00192-g004){#F4}

![Typical ^1^H NMR (600 MHz) spectroscopy of serum sample with the differential metabolites labeled. Numbers represent differential metabolites identified between the CUMS group and the control group.](fphar-10-00192-g005){#F5}

![Multivariate data analysis from UPLC-MS/MS. **(A)** PLS-DA score plots, **(B)** PLS-DA model validation diagram, **(C)** OPLS-DA score plots, **(D)** S-plot of OPLS-DA, **(E)** PLS-DA score plots of serum samples collected from different groups.](fphar-10-00192-g006){#F6}

![Multivariate data analysis from NMR. **(A)** PLS-DA score plots, **(B)** PLS-DA model validation diagram, **(C)** OPLS-DA score plots, **(D)** S-plot of OPLS-DA, **(E)** PLS-DA score plots of serum samples collected from different groups.](fphar-10-00192-g007){#F7}

### Identification of Endogenous Metabolites

Significantly differential metabolites were screened according to the VIP values of S-plots (\>1.0) and *T*-tests (*p* \< 0.05). The metabolites obtained from LC-MS analysis were identified according to MS/MS fragments, retention behavior and online databases. As a consequence, a total of 24 endogenous biomarkers in serum were screened ([Table 1](#T1){ref-type="table"}). The metabolites obtained from NMR analysis were identified based on moieties and chemical shifts, and 17 endogenous biomarkers were screened ([Table 2](#T2){ref-type="table"}). The level of 3-Hydroxybutyrate, lactate, alanine, glutamine, taurine, TMAO, β-Glucose, glycine, α-Glucose, allantoin, pipecolic acid, 3-Indoxyl sulfate, cholic acid, phytosphingosine, octadecenylcarnitine, 20-COOH-leukotriene E4, sphingosine, LysoPC (20:5), deoxycholic acid, LysoPC (16:0), and 20-Oxo-leukotriene E4 was significantly increased in the CUMS group as compared to the control group. The level of lipid, isoleucine, acetone, pyruvate, citrate, creatine, choline, glutamic acid, proline, valine, methionine, propionylcarnitine, leucine, tryptophan, indoleacrylic acid, palmitoylcarnitine, oleamide, and stearamide was significantly decreased in the CUMS group as compared to the control group. The variation of endogenous biomarkers from LC-MS is illustrated in [Figure 8](#F8){ref-type="fig"}, and that from NMR is illustrated in [Figure 9](#F9){ref-type="fig"}. A total of 26 metabolites including lipid, isoleucine, 3-Hydroxybutyrate, lactate, alanine, citrate, glutamine, choline, taurine, β-Glucose, glycine, α-Glucose, allantoin, glutamic acid, proline, valine, methionine, leucine, tryptophan, cholic acid, octadecenylcarnitine, 20-COOH-leukotriene E4, sphingosine, deoxycholic acid, oleamide, and palmitoylcarnitine was intervened by AS treatment. VLF treatment also exerted an effect on these metabolic alterations to a certain extent, while the effect was weaker than AS.

###### 

Differential metabolites associated with depression were detected by UPLC-MS/MS.

  No.      Metabolites               *T*~R~ (min)   m/z        Formula               VIP    *P*     Fold change   Trend   HMDB ID   Scan mode
  -------- ------------------------- -------------- ---------- --------------------- ------ ------- ------------- ------- --------- -----------
  \(1\)    Glutamic acid^a^          1.31           148.0604   C~5~H~9~NO~4~         1.41   ^∗∗^    0.75          ↓       00148     \+
  \(2\)    Proline                   1.42           116.0706   C~5~H~9~NO~2~         2.60   ^∗^     0.78          ↓       00162     \+
  \(3\)    Valine^a^                 1.50           118.0863   C~5~H~11~NO~2~        4.17   ^∗∗∗^   0.48          ↓       00883     \+
  \(4\)    Methionine                1.65           150.0583   C~5~ H~11~ N O~2~ S   2.56   ^∗^     0.86          ↓       00696     \+
  \(5\)    Propionylcarnitine        1.66           218.1387   C~10~H~19~NO~4~       1.83   ^∗^     0.71          ↓       00824     \+
  \(6\)    Pipecolic acid            1.67           128.0717   C~6~H~11~NO~2~        2.12   ^∗∗^    2.02          ↑       00070     \-
  \(7\)    Leucine^a^                3.49           132.1019   C~6~H~13~NO~2~        1.52   ^∗∗∗^   0.79          ↓       00687     \+
  \(8\)    Tryptophan^a^             5.75           205.0972   C~11~H~12~N~2~O~2~    1.24   ^∗∗∗^   0.79          ↓       00929     \+
  \(9\)    3-Indoxyl sulfate         6.30           212.0023   C~8~H~7~NO~4~S        2.28   ^∗∗^    1.96          ↑       00682     \-
  \(10\)   Indoleacrylic acid        7.92           188.0706   C~11~H~9~NO~2~        1.16   ^∗∗^    0.51          ↓       00734     \+
  \(11\)   Cholic acid               10.19          409.2949   C~24~H~40~O~5~        2.29   ^∗∗^    3.18          ↑       00619     \+
  \(12\)   Phytosphingosine          11.67          318.3003   C~18~H~39~NO~3~       1.13   ^∗^     1.51          ↑       04610     \+
  \(13\)   Octadecenylcarnitine      12.06          426.3581   C~24~H~43~NO~5~       3.25   ^∗∗^    3.81          ↑       13338     \+
  \(14\)   20-COOH-leukotriene E4    12.07          470.2583   C~24~H~41~NO~4~P~2~   1.75   ^∗∗^    2.63          ↑       12634     \+
  \(15\)   Sphingosine               15.30          300.2897   C~18~ H~37~ N O~2~    1.70   ^∗∗∗^   3.54          ↑       00252     \+
  \(16\)   LysoPC (20:5)             15.44          542.3241   C~28~H~48~NO~7~P      1.39   ^∗∗^    1.41          ↑       10397     \+
  \(17\)   Deoxycholic acid          15.65          393.2999   C~24~H~40~O~4~        2.90   ^∗∗^    2.74          ↑       00626     \+
  \(18\)   LysoPC (16:0)             17.27          496.3403   C~24~H~50~NO~7~P      4.13   ^∗^     1.10          ↑       10382     \+
  \(19\)   20-Oxo-leukotriene E4     17.75          454.2928   C~21~H~44~NO~7~P      3.02   ^∗∗∗^   1.25          ↑       12642     \+
  \(20\)   Choline                   17.92          104.1070   C~5~H~13~NO           1.73   ^∗∗∗^   0.85          ↓       00097     \+
  \(21\)   Palmitoylcarnitine        18.53          400.3421   C~23~H~45~NO~4~       1.28   ^∗∗^    0.62          ↓       00222     \+
  \(22\)   Oleamide                  26.70          282.2791   C~18~H~35~NO          1.81   ^∗∗^    0.33          ↓       02117     \+
  \(23\)   Stearamide                29.02          284.2948   C~18~H~37~NO          2.81   ^∗^     0.53          ↓       34146     \+
  \(24\)   Palmitoyl sphingomyelin   30.98          703.5749   C~39~H~79~N~2~O~6~P   1.10   ^∗^     1.43          ↑                 \+
                                                                                                                                    

"↓" or "↑" means the metabolite significantly decreased or increased in the CUMS group compared with control group.

∗

p \< 0.05,

∗∗

p \< 0.01,

∗∗∗

p \< 0.001 compared with control group.

a

Validated with standard.

###### 

Differential metabolites associated with depression were detected by NMR.

  No.      Metabolites         Chemical shift                          VIP    *P*     Fold change   Trend   HMDB ID
  -------- ------------------- --------------------------------------- ------ ------- ------------- ------- ---------
  \(1\)    Lipid               0.86(m), 1.28(m), 2.78(m), 5.30(m)      4.64   ^∗^     0.64          ↓       13244
  \(2\)    Isoleucine          0.94(t), 1.01(d), 1.27(m)               3.31   ^∗∗^    0.81          ↓       00172
  \(3\)    3-hydroxybutyrate   1.20(d), 2.41(d), 2.31(d)               2.03   ^∗∗^    1.50          ↑       00357
  \(4\)    Lactate             1.33(d), 4.12(q)                        3.10   ^∗∗^    1.21          ↑       00190
  \(5\)    Alanine             1.48(d), 3.77(q)                        1.48   ^∗∗^    1.22          ↑       00161
  \(6\)    Glutamine           2.14(m), 2.46(m)                        3.21   ^∗^     1.18          ↑       00641
  \(7\)    Acetone             2.23(s)                                 1.67   ^∗^     0.72          ↓       01659
  \(8\)    Pyruvate            2.37(s)                                 2.28   ^∗∗^    0.69          ↓       00243
  \(9\)    Citrate             2.54(d), 2.70(d)                        1.14   ^∗∗∗^   0.82          ↓       00094
  \(10\)   Creatine            3.04(s), 3.94(s)                        2.84   ^∗∗^    0.74          ↓       00064
  \(11\)   Choline             3.20(s)                                 1.56   ^∗∗^    0.66          ↓       00097
  \(12\)   Taurine             3.26(t), 3.41(t)                        3.55   ^∗^     1.26          ↑       00251
  \(13\)   TMAO                3.27(s)                                 3.27   ^∗∗^    1.19          ↑       00925
  \(14\)   β-Glucose           3.49(t), 3.41(dd), 3.73(dd), 3.90(dd)   4.92   ^∗∗^    1.23          ↑       00122
  \(15\)   Glycine             3.56(s)                                 2.30   ^∗∗^    1.22          ↑       00123
  \(16\)   α-Glucose           5.24(d), 3.54(d)                        3.67   ^∗∗∗^   1.67          ↑       00122
  \(17\)   Allantoin           5.38(s)                                 1.46   ^∗^     1.43          ↑       00462
                                                                                                            

"↓" or "↑" means the metabolite significantly decreased or increased in the CUMS group compared with control group.

∗

p \< 0.05,

∗∗

p \< 0.01,

∗∗∗

p \< 0.001 compared with control group.

![Comparison of relative peak areas of the differential metabolites in UPLC-MS/MS associated with drug treatment. The data are presented as means ± SD (*n* = 9). ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, ^\#\#\#^*p* \< 0.001 compared with control group; ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 compared with the CUMS group.](fphar-10-00192-g008){#F8}

![Comparison of the relative intensity of differential metabolites in NMR associated with drug treatment. The data are presented as means ± SD (*n* = 6). ^\#^*p* \< 0.05, ^\#\#^*p* \< 0.01, ^\#\#\#^*p* \< 0.001 compared with control group; ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 compared with the CUMS group.](fphar-10-00192-g009){#F9}

### Metabolic Pathway Analysis

Twenty-four endogenous biomarkers identified from LC-MS and 16 from NMR were, respectively, imported into the MetaboAnalyst, to explore the potential metabolic pathways of depression. The metabolic pathways are summarized in [Figure 10](#F10){ref-type="fig"}. According to the biomarkers identified from LC-MS, [D]{.smallcaps}-Glutamine and [D]{.smallcaps}-glutamate metabolism with an impact-value of 1.0, valine, leucine and isoleucine biosynthesis with an impact-value of 0.67, alanine, aspartate and glutamate metabolism with an impact-value of 0.26, tryptophan metabolism with an impact-value of 0.16, and arginine and proline metabolism with an impact-value of 0.16 were filtered out as the most significant metabolic pathways with an impact-value over 0.10. Based on the biomarkers identified from NMR, the main changed metabolic pathways of depression were taurine and hypotaurine metabolism (impact-value 0.43); valine, leucine and isoleucine biosynthesis (impact-value 0.33); glyoxylate and dicarboxylate metabolism (impact-value 0.30); glycine, serine and threonine metabolism (impact-value 0.29); pyruvate metabolism (impact-value 0.19); alanine, aspartate and glutamate metabolism (impact-value 0.15); citrate cycle (impact-value 0.13); and glycolysis or gluconeogenesis (impact-value 0.10).

![Summary of pathway analysis of serum samples collected from CUMS rats. **(A)** Pathway analysis from UPLC-MS/MS. **(B)** Pathway analysis from NMR. (a) [D]{.smallcaps}-Glutamine and [D]{.smallcaps}-glutamate metabolism, (b) valine, leucine and isoleucine biosynthesis, (c) taurine and hypotaurine metabolism, (d) glyoxylate and dicarboxylate metabolism, (e) glycine, serine and threonine metabolism, (f) alanine, aspartate and glutamate metabolism, (g) pyruvate metabolism, (h) tryptophan metabolism, (i) arginine and proline metabolism, (j) TCA cycle, (k) glycolysis or gluconeogenesis metabolism.](fphar-10-00192-g010){#F10}

The Relation of Disturbed Metabolites Related by Angelicae Sinensis Radix Between Depression and Anemia
-------------------------------------------------------------------------------------------------------

To investigate the linkage between the effect of anti-depression and modulating the blood system of AS, the disturbed metabolites regulated by AS in anemia were mined according to previous literature. Briefly, two keywords including AS and metabonomics were inputted into PubMed^[8](#fn08){ref-type="fn"}^ to search the literature, the obtained literature associated with anemia was further filtrated out. As a result, five studies in the literature, which reported that disturbed metabolites were regulated in anemia through the administration of AS, were screened, and these metabolites were further compared with those regulated in depression by AS in the current study. As presented in [Figure 11](#F11){ref-type="fig"}, a total of eight biomarkers including valine, glucose, glycine, lactate, proline, citrate, sphingosine, and alanine were regulated by AS both in depression and anemia. These metabolites mainly participate in the metabolic pathways including the TCA cycle, amino acid, carbohydrate and sphingolipid metabolism. The mechanism may be associated with the promotion of the body's energy metabolism, the stabilization of the cell membrane, the promotion of serum protein synthesis, and the enhancement of immunity ([Figure 12](#F12){ref-type="fig"}).

![Summary of shared metabolites regulated by AS both in depression and anemia. Metabolites in red circle represents the disturbed metabolites regulated by AS in depression, metabolites in blue circle represents the disturbed metabolites regulated by AS in anemia. Eight biomarkers included valine, glucose, glycine, lactate, proline, citrate, sphingosine, and alanine are the shared metabolites.](fphar-10-00192-g011){#F11}

![Potential anti-depression mechanisms of AS related to the activity of modulating the blood system. "↓" or "↑" means the metabolite significantly decreased or increased in AS group compared with the CUMS group.](fphar-10-00192-g012){#F12}

Effects of Angelicae Sinensis Radix on the Expression of LDHA and PDK-1
-----------------------------------------------------------------------

The expression of critical proteins on energy metabolism was further determined to validate the metabolic results. PDK-1 could inhibit the activity of pyruvate dehydrogenase complex (PDC) and block the production of acetyl coenzyme A, which acts as an intermediate metabolite of energy metabolism. LDHA catalyzes the interconversion of pyruvate and NADH to lactate and NAD^+^. The results are presented in [Figure 13A,B](#F13){ref-type="fig"}. The level of PDK-1 and LDHA was significantly elevated in the liver of rats in the CUMS group compared with that in the control group, suggesting that energy metabolism was disrupted after the CUMS procedure. However, the elevated level of PDK-1 and LDHA was obviously decreased after the treatment with AS. The results proved that AS could relieve depression syndrome by regulating energy metabolism.

![Effects of Angelicae Sinensis Radix on the expression level of LDHA and PDK-1. **(A)** LDHA proteins. **(B)** PDK-1 proteins. The data are presented as means ± SD. ^\#\#^*p* \< 0.01 compared with control group; ^∗∗^*p* \< 0.01 compared with the CUMS group.](fphar-10-00192-g013){#F13}

Discussion
==========

Angelicae Sinensis Radix, a famous TCM herb wildly used in Asia for thousands of years, has in recent years been confirmed to have an anti-depression. Our present study demonstrates that AS significantly improves the depressive symptom induced by CUMS as described in previous reports ([@B32]). AS could significantly increase the decreased body weight, sucrose preference and locomotor activity induced by the CUMS procedure, and reduce the increased immobility time in FST induced by the CUMS procedure. AS (low dose and high dose) could increase a more reduced body weight than VLF. It is speculated that AS extract is rich in polysaccharides, which could turn to fat *in vivo*.

Accumulating evidence has suggested that depressive symptoms are associated with anemia. It has been proposed that depression could be ameliorated via modulating the blood system. AS is applied for invigorating blood circulation and enriching blood traditionally. Therefore, we speculated that the anti-depression effect of AS may be related to the pharmacological activity of modulating the blood system. In the current study, our results demonstrated that the blood circulation system was exactly disordered by the CUMS procedure, which could be significantly reversed by the treatment of AS. AS showed a higher activity than VLF on the effect of regulating the blood system, which is in accordance with the "multi-component and multi-target pattern" of TCM.

Red blood cell distribution width is a parameter representing the coefficient of variation of the red blood cell volume distribution and can be considered as a more sensitive indicator to establish the origin of microcytic hypochromic anemia ([@B2]). RDW and MCV can be applied for the morphological classification of anemia ([@B3]). In the current study, the level of MCV was decreased and the level of RDW was increased in the model group, suggesting that iron deficiency anemia occurred in the CUMS procedure ([@B36]). These results agrees with the literature, i.e., RDW level was elevated and MCV level was reduced in depressive patients as evidenced in previous reports ([@B10]; [@B4]). In this study, we discovered that anemia accompanied depression, however, the level of RBC was conversely increased in the model group and no significant difference was observed in hemoglobin concentration (Hb) between the CUMS and control group (data not shown). This may be because in the early period of iron deficiency anemia, the absence of iron results in a reduction of heme and hemoglobin, which induces a compensatory elevation of RBC ([@B16]). On the other hand, the elevation of RBC in the CUMS group could be partly ascribed to stress polycythemia (Gaisböck syndrome), a pathological state with abnormally increasing erythrocyte in the blood which is often seen in distorted personality (nervosity, cyclothymia, or depression) or active individuals under emotional stress ([@B22]). Additionally, thrombocythemia is often seen in erythrocytosis. The elevated PLT in the CUMS group could therefore be associated with the elevation of RBC. In the current study, we found that these disordered peripheral blood indicators were regulated to a normal level after the administration of AS.

An increasing body of research has indicated that vascular dysfunction plays a crucial role in the development of MDD. Angiogenesis and neurogenesis is interdependent in the neurogenic/neurotrophic theory of depression. The trophic factors VEGF may serve as a common thread that connects angiogenesis and neurogenesis ([@B11]). Hypoxia is a common finding in depression, which is ascribed to capillary dysfunction ([@B24]). Inflammation is triggered to help tissues adapt to hypoxia. The vicious spiral of capillary dysfunction, hypoxia and inflammation affects the synthesis of the neurotransmitter serotonin, which finally accelerates the development of depression. Graphic representation of the hypotheses for the association of depression, anemia and hypoxia was shown in [Figure 14](#F14){ref-type="fig"}. Our current study suggests that obvious symptoms of hypoxia were observed after the CUMS procedure which could be improved by the treatment of AS, due to the pharmacological action of AS of promoting capillary generation.

![Graphic representation of the hypotheses for the association of depression, anemia and hypoxia.](fphar-10-00192-g014){#F14}

Hyperactivity of the hypothalamic-pituitary-axis has commonly been considered as the pathogenesis of major depression. Evidence has suggested that the abnormality of energy metabolism in depression may be associated with excess glucocorticoids (GC). On the one hand, high levels of GC exposure result in the deterioration of mitochondrial function by interfering with the proton gradients across their mitochondria's inner membranes ([@B9]; [@B14]). On the other hand, high levels of GC affect the body's energy expenditures. The body's energy balance shifts from anabolism toward catabolism, which finally results in lipolysis in adipose tissue and protein degradation in muscle and bones, to mobilize available energy resources ([@B24]). Our metabonomics results demonstrated that metabolites such as pyruvate, citrate, lactate, and glucose, involved in energy metabolism, were disturbed in the CUMS group, indicating an imbalance of energy metabolism, which may be due to hypoxia and the excess of GC. The level of citrate, lactate and glucose was significantly reversed by the administration of AS, suggesting that AS could relieve depression syndrome by improving energy metabolism. Compared with the AS group, the oxygen content level (PO~2~ and sO~2~) upregulated by VLF was lower. The lower oxygen content in the VLF group resulted in a disorder of the TCA cycle, followed by a decrease of citrate. Therefore, the level of citrate was higher in the AS group than that in the VLF group. The decreased oxygen content in the VLF group resulted in a promotion of anaerobic metabolism, which was followed by a lactate elevation. As a result, the abnormally decreased pH value could not be significantly reversed by the administration of VLF.

Sphingolipids play a crucial role in the composition of the cell membrane and participate in the many signaling processes, such as cell growth, differentiation, and programmed cell death ([@B35]). Sphinganine, sphinganine 1-phosphate, ceramide, and phytosphingosine are disturbed during the process of anemia, which may be associated with the injured erythrocyte membrane and disordered peripheral blood indicators ([@B19]; [@B26]). AS could significantly down-regulate the increased sphingolipids and phytosphingosine induced by anemia, suggesting that AS could relieve anemia syndrome by regulating the sphingolipid metabolism. In the current study, we demonstrated that sphinganine and phytosphingosine were significantly increased in the CUMS group, while sphinganine was significantly decreased after the administration of AS. Sphingolipid metabolism acts as a common thread that connects depression and anemia. The syndrome of anemia, accompanied by depression could be relieved by AS through sphingolipid metabolism, which finally results in the amelioration of depression. A down-regulation tendency in sphingosine, which participates in the composition of the cell membrane ([@B35]), was also observed in the VLF group. However, the effect was weaker than that in the AS group. Thus, the modulation effect of VLF on RBC composed of sphingosine, was also weaker than that of AS.

Several amino acids have been regarded as important biomarkers related to anemia. In the case of blood deficiency, valine regulates blood sugar levels and supply extra energy to muscles ([@B1]). Thus, valine is significantly decreased in the model of anemia. Glycine has been reported to regulate serum iron and promote the synthesis of serum protein. The elevation of the glycine level in the case of anemia could be associated with the protection of ischemic cell and the improvement of immune function ([@B17]). Alanine plays a crucial role in immune function and the regeneration of lymphocytes ([@B23]). The reduction of alanine in the case of anemia could be related to damage of the immune function. In the current study, we found that nine amino acids were disturbed in the procedure of CUMS, indicating a disturbance of amino acid metabolism. In accordance with the disturbed amino acids regulated by AS in anemia, four amino acids including valine, glycine, alanine, and proline were also regulated by the administration of AS in depression. These finding suggested that the syndrome of anemia accompanied by depression could be relieved by AS, through an amino acid metabolism, which finally results in the amelioration of depression.

Conclusion
==========

Angelicae Sinensis Radix could significantly improve the CUMS-induced depressive symptoms, anemia symptoms, and hypoxia symptoms. The analysis of metabonomics suggested that the anti-depression effect of AS was related to the function of modulating the blood system, which is mainly associated with the metabolic pathways including energy, amino acid, and sphingolipid metabolism. The mechanism may be associated with the promotion of the body's energy metabolism, the stabilization of the cell membrane, the promotion of serum protein synthesis, and the enhancement of immunity.
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